SMARCB1 is a critical component of the BAF complex that is responsible for global chromatin remodeling. Loss of SMARCB1 has been implicated in the initiation of cancers such as malignant rhabdoid tumor (MRT), atypical teratoid rhabdoid tumor (ATRT), and, more recently, renal medullary carcinoma (RMC). These SMARCB1-deficient tumors have remarkably stable genomes, offering unique insights into the epigenetic mechanisms in cancer biology. Given the lack of druggable targets and the high mortality associated with SMARCB1-deficient tumors, a significant research effort has been directed toward understanding the mechanisms of tumor transformation and proliferation. Accumulating evidence suggests that tumorigenicity arises from aberrant enhancer and promoter regulation followed by dysfunctional transcriptional control. In this review, we outline key mechanisms by which loss of SMARCB1 may lead to tumor formation and cover how these mechanisms have been used for the design of targeted therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332782 | PMC |
| http://dx.doi.org/10.3390/cancers14153645 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Atypical teratoid rhabdoid tumor (ATRT) is the most common malignant brain tumor in infants, and more than 60% of children with ATRT die from their tumor. ATRT is associated with mutational inactivation/deletion of , a member of the SWI/SNF chromatin remodeling complex, suggesting that epigenetic events play a critical role in tumor development and progression. Moreover, disruption of SWI/SNF allows unopposed activity of epigenetic repressors, which contribute to tumorigenicity.
View Article and Find Full Text PDFParatesticular/inguinal SMARCB1/INI1 deficient carcinomas with yolk sac tumour-like differentiation are aggressive somatic malignancies.
Histopathology
January 2025
Department of Diagnostic and Molecular Pathology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Aims: Extragonadal yolk sac tumour (YST) is rare, and may present a diagnostic challenge. YST differentiation was recently reported in some somatically derived tumours in the sinonasal location and in the female genital tract, together with a SMARCB1/INI1 loss. We report two paratesticular/inguinal tumours with striking morphological and immunohistochemical similarities with YST, further expanding the spectrum of extragonadal tumours with YST-like morphology and SMARCB1/INI1 loss.
View Article and Find Full Text PDFSMARCA4-deficient epithelioid sarcoma revealed by comprehensive genomic profiling, leading to a notable response by nivolumab treatment.
Int Cancer Conf J
January 2025
Department of Hematology and Medical Oncology, Kanagawa Cancer Center, 2-3-2, Nakao, Asahi, Yokohama, Kanagawa 2418515 Japan.
Article Synopsis
- A 50-year-old man presented with a large mass in his left thigh causing significant pain and impaired functionality, with imaging showing widespread tumors in several body parts, but the primary cancer source was unknown.
- Despite rapid tumor progression, he began treatment with nivolumab, an immunotherapy drug, and further genomic profiling led to a re-diagnosis of SMARCA4-deficient epithelioid sarcoma.
- After 5 weeks of treatment, the patient showed significant improvement despite facing some immune-related side effects; by the 12th dose, he had a positive response to the therapy with no new complications.
[Small cell carcinoma of the ovary of hypercalcaemic type: a clinicopathological analysis of sixteen cases].
Zhonghua Bing Li Xue Za Zhi
December 2024
Department of pathology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai200011, China.
Article Synopsis
- This study examined 16 cases of small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), focusing on clinical features, molecular traits, and family genetics over a decade at Fudan University.
- Patients had a mean diagnosis age of 28.7 years, with unique tumor characteristics; most were unilateral, with significant sizes, and misdiagnosed in many cases, while specific protein expressions were analyzed.
- Survival rates over time were low, with only 22.6% surviving two years, highlighting the need for accurate diagnosis and better understanding of the disease's genetic components.
Switch/Sucrose Non-Fermentable (SWI/SNF) Complex-Partial Loss in Sinonasal Squamous Cell Carcinoma: A High-Grade Morphology Impact and Progression.
Curr Issues Mol Biol
October 2024
Oral and Maxillofacial Pathology Department, Postgraduate Dental School, National Autonomous University of Mexico, Mexico City 04510, Mexico.
Unlabelled: Sinonasal carcinomas are aggressive neoplasms that present a high morbidity and mortality rate with an unfavorable prognosis. This group of tumors exhibits morphological and genetic diversity. Genetic and epigenetic alterations in these neoplasms are the current targets for diagnosis and treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!